NYRADA INC. — Capital/Financing Update 2024

Nov 3, 2024

==> picture [596 x 108] intentionally omitted <==

4 November 2024

Sydney, Australia

Cleansing Notice for Security Purchase Plan

Nyrada Inc. ARBN 625 401 818 ( Nyrada or the Company ) (ASX: NYR) refers to its announcement 28 October 2024 regarding the opportunity for eligible CDI holders to purchase up to $30,000 worth of new fully paid CHESS Depositary Interests ( CDIs ) in the Company under a Security Purchase Plan ( SPP ).

The SPP will be offered in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 .

It is a condition of that instrument that the Company issue this notice before the SPP offer is made. The SPP is expected to open (and the SPP offer made) from 9.00am (Sydney time) on 4 November 2024.

Accordingly, the Company gives the ASX (as the relevant market operator) notice that:

1. the Company will make offers to issue CDIs under the SPP without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) ( Corporations Act );

2. this notice is given in accordance with section 7(f)(ii) of the ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 ;

3. as at the date of this notice, the Company has complied with:

4. a. the provisions of Chapter 2M of the Act as they apply to the Company; and

5. b. section 674 of the Corporations Act; and

6. as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act in relation to the Company.

For and on behalf of the Board of Nyrada Inc.

Yours faithfully,

David Franks Company Secretary

-ENDS-

Page 1

Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072

ARBN 625 401 818

==> picture [596 x 108] intentionally omitted <==

About Nyrada Inc

Nyrada Inc. is a biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company’s lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. John Moore, Chair on behalf of the Board.

Investor: Company Secretary: Dimitri Burshtein David Franks T: 02 9498 3390 T: 02 8072 1400 E: info@nyrada.com E: david.franks@automicgroup.com.au

Media Enquiries:

Catherine Strong Sodali & Co T: 02 8234 0111 E: catherine.strong@sodali.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forwardlooking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Page 2

Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072

ARBN 625 401 818